Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Research & Development, LLC
This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo-controlled (an inactive substance that is compared with a medication to test whether the medication has a real effect), parallel-group, multicenter study of the effects of canagliflozin and phentermine co-administration in non-diabetic overweight or obese participants. The study will be conducted for about 33 weeks, approximately 344 participants will be randomly assigned in a 1:1:1:1 ratio to one of the four treatment groups: co-administration of canagliflozin and phentermine, canagliflozin alone, phentermine alone, or placebo. All participants will be also provided with diet and exercise counseling for weight loss (standardized non-pharmacological therapy).
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have BMI \>=30 kg/m2 and \<50 kg/m2 at screening or BMI \>=27 kg/m2 and \<50 kg/m2 at screening in the presence of a comorbidity of hypertension and/or dyslipidemia
Must have stable weight, ie, change of \< =5% in the 3 months before screening
Must agree to utilize a highly effective method of birth control
You may not be if
An established diagnosis of diabetes mellitus
Has a history of obesity with a known secondary cause (eg, Cushing's disease/syndrome)
Has a history of hereditary glucose-galactose malabsorption or primary renal glycosuria
Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident within 12 weeks before screening
Has an Glycated hemoglobin (HBA1c) greater than or equal (\>=) to 65 percent
An average of 3 seated blood pressure (BP) readings of systolic BP \>= 160 mm Hg and/or Diastolic BP \>= 100 millimeters of mercury at screening